Drugs

, Volume 72, Issue 7, pp 917–930 | Cite as

Bevacizumab Combination Therapy

For the First-Line Treatment of Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Adis Drug Profile

Abstract

Bevacizumab is a recombinant, humanized antivascular endothelial growth factor (VEGF) monoclonal antibody that neutralizes the biological activity of VEGF and inhibits tumour angiogenesis.

In two pivotal, well designed, phase III, clinical trials (GOG-0218 and ICON7) in women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, first-line treatment with bevacizumab in combination with standard chemotherapy (carboplatin plus paclitaxel) followed by maintenance treatment with bevacizumab alone significantly prolonged progression-free survival relative to standard chemotherapy.

A subgroup analysis of ICON7 suggested that bevacizumab therapy may also be beneficial in patients at high risk of disease progression.

In GOG-0218, health-related quality of life (HR-QOL) deteriorated temporarily (during the chemotherapy phase) and slightly, although statistically significantly, with bevacizumab in combination with standard chemotherapy followed by bevacizumab maintenance relative to standard chemotherapy plus placebo maintenance. In ICON7, HR-QOL did not differ to a clinically significant extent between patients receiving bevacizumab plus standard chemotherapy followed by bevacizumab maintenance and those receiving standard chemotherapy alone.

Bevacizumab combination therapy had generally acceptable tolerability in these studies, with the nature of adverse events generally similar to that observed in previous clinical trials in patients with other solid tumours.

References

  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011 Mar 30; 61 (2): 69–90PubMedCrossRefGoogle Scholar
  2. 2.
    Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 Suppl. 5: v23-30Google Scholar
  3. 3.
    Vaughan S, Coward JI, Bast RCJ, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011 Oct; 11 (10): 719–25PubMedCrossRefGoogle Scholar
  4. 4.
    Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007; 25 (20): 2902–8PubMedCrossRefGoogle Scholar
  5. 5.
    Ledermann JA, Marth C, Carey MS, et al. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer 2011; 21 (4): 763–70PubMedCrossRefGoogle Scholar
  6. 6.
    Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011 Jan; 18 (1): 31–43PubMedGoogle Scholar
  7. 7.
    Kerbel RS. Tumor angiogenesis. N Engl J Med 2008 May 8; 358 (19): 2039–49PubMedCrossRefGoogle Scholar
  8. 8.
    Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999 Jan 1; 85 (1): 178–87PubMedCrossRefGoogle Scholar
  9. 9.
    Brustmann H. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol 2004 Oct; 95 (1): 16–22PubMedCrossRefGoogle Scholar
  10. 10.
    Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloprotei-nases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003 Sep; 39 (13): 1948–56PubMedCrossRefGoogle Scholar
  11. 11.
    Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003 Dec; 91 (3): 513–7PubMedCrossRefGoogle Scholar
  12. 12.
    European Medicines Agency. Avastin (bevacizumab): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf [Accessed 2012 Jan 12]
  13. 13.
    European Medicines Agency. Avastin (bevacizumab): summary of opinion, post authorisation (EMA/CHMP/569545/2011) [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000582/WC500112811.pdf [Accessed 2011 Nov 18]
  14. 14.
    Lyseng-Williamson KA, Robinson DM. Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer 2006; 5 (1): 43–60CrossRefGoogle Scholar
  15. 15.
    Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007; 67 (12): 1793–9PubMedCrossRefGoogle Scholar
  16. 16.
    Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011 Nov 12; 71 (16): 2213–29PubMedCrossRefGoogle Scholar
  17. 17.
    Gerber HP, Ferrara N. Pharmacology and pharmaco-dynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005 Feb 1; 65 (3): 671–80PubMedGoogle Scholar
  18. 18.
    Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7 (4): 335–45PubMedCrossRefGoogle Scholar
  19. 19.
    Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14 (23): 7781–9PubMedCrossRefGoogle Scholar
  20. 20.
    Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006 Feb 10; 24 (5): 769–77PubMedCrossRefGoogle Scholar
  21. 21.
    Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19 (3): 843–50PubMedGoogle Scholar
  22. 22.
    Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19 (3): 851–6PubMedGoogle Scholar
  23. 23.
    Hsei V, Deguzman GG, Nixon A, et al. Complexation of VEGF with bevaczumab decreases VEGF clearance in rats. Pharm Res 2002; 19 (11): 1753–6PubMedCrossRefGoogle Scholar
  24. 24.
    Mabuchi S, Kawase C, Altomare DA, et al. Vascular endo-thelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 2010 Aug; 9 (8): 2411–22PubMedCrossRefGoogle Scholar
  25. 25.
    Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57 (20): 4593–9PubMedGoogle Scholar
  26. 26.
    Yanagisawa M, Yorozu K, Kurasawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 2010; 21 (7): 687–94PubMedGoogle Scholar
  27. 27.
    Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362 (6423): 841–4PubMedCrossRefGoogle Scholar
  28. 28.
    Hu L, Hofmann J, Zaloudek C, et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002 Nov; 161 (5): 1917–24PubMedCrossRefGoogle Scholar
  29. 29.
    Belotti D, Calcagno C, Garofalo A, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 2008 Apr; 6 (4): 525–34PubMedCrossRefGoogle Scholar
  30. 30.
    Smerdel MP, Steffensen KD, Waldstrom M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010; 118 (2): 167–71PubMedCrossRefGoogle Scholar
  31. 31.
    Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010; 119 (3): 484–90PubMedCrossRefGoogle Scholar
  32. 32.
    Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117 (3): 497–504PubMedCrossRefGoogle Scholar
  33. 33.
    Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010 May; 11 (5): 465–75PubMedCrossRefGoogle Scholar
  34. 34.
    Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009 Mar; 43 (3): 490–501PubMedCrossRefGoogle Scholar
  35. 35.
    Wu JY, Wu XN, Ding L, et al. Phase I safety and pharma-cokinetic study of bevacizumab in Chinese patients with advanced cancer. Chin Med J 2010; 123 (7): 901–6PubMedGoogle Scholar
  36. 36.
    European Medicines Agency. Avastin: European public assessment report: scientific discussion [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000582/WC500029262.pdf [Accessed 2011 Nov 29]
  37. 37.
    Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011 Dec 29; 365 (26): 2473–83PubMedCrossRefGoogle Scholar
  38. 38.
    Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011 Dec 29; 365 (26): 2484–96PubMedCrossRefGoogle Scholar
  39. 39.
    Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007; 17 (4): 771–6PubMedCrossRefGoogle Scholar
  40. 40.
    Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mullerian tumors. J Clin Oncol 2010; 28 (1): 154–9PubMedCrossRefGoogle Scholar
  41. 41.
    Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001 Mar 15; 19 (6): 1809–17PubMedGoogle Scholar
  42. 42.
    Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003 Jul; 39 (10): 1402–8PubMedCrossRefGoogle Scholar
  43. 43.
    Burger R, Brady M, Bookman M, et al. Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group study [abstract no. 7]. Gynecol Oncol 2011; 120 Suppl. 1: S5Google Scholar
  44. 44.
    Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011; 29 (10): 1247–51PubMedCrossRefGoogle Scholar
  45. 45.
    Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000; 19 (2): 92–109CrossRefGoogle Scholar
  46. 46.
    Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value?. Oncologist 2006; 11 (2): 90–5PubMedCrossRefGoogle Scholar
  47. 47.
    Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011; 21 (4): 756–62PubMedCrossRefGoogle Scholar
  48. 48.
    Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [abstract]. J Clin Oncol 2011; 29 (15 Suppl.)Google Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations